Cannabis and sleep – How CBD and CBN help with insomnia? Sleep architecture, dosages, evidence 2024

According to the report Sleep Foundation As of 2024, insomnia symptoms affect 30-35% of adults in developed countries, and chronic insomnia (lasting over 3 months) affects 10-15% of the population. A Polish study EZOP II (Institute of Psychiatry and Neurology, 2021) estimates that one in four adult Poles reports sleep problems. It's no wonder that cannabis, specifically cannabidiol (CBD) and cannabinol (CBN), has made it onto the list of "natural hopes" for a better night. But how much of this is medicine and how much is marketing? This article breaks down how CBD affects sleep, what CBN really is, how sleep architecture looks, and when a neurologist is needed instead of oil. All with references to clinical research and Polish legal realities.

Short answer: how do CBD and CBN help with insomnia?

CBD helps with falling asleep mainly indirectly, by reducing anxiety and calming the "race of thoughts" (Shannon et al., Permanente Journal, 2019: 66.7% of patients reported improved sleep, 79.2% reported reduced anxiety). CBN is sometimes referred to as the "sleep cannabinoid," but current data is weak and does not confirm a strong hypnotic effect.

In short: CBD has more evidence for improving subjective sleep quality, although it does not induce sleep directly. CBN is an interesting molecule, whose sedative role remains a hypothesis based mainly on animal studies from the 1970s (Karniol et al., 1975) and the entourage effect with terpenes (myrcene, linalool). CBD+CBN combinations are popular, but clinical effectiveness is only partially proven.

Shannon et al. (2019) described in Permanente Journal a retrospective series of 72 patients with anxiety and sleep disorders receiving 25 mg of CBD per day. After a month, 66.7% of patients reported improved sleep, and 79.2% reported reduced anxiety. The effect persisted for three months of observation.

Sleep Cycles 101: why does sleep architecture matter?

According to the American Academy of Sleep Medicine (AASM, 2023) an adult needs 7-9 hours of sleep, organized into 4-6 cycles of about 90 minutes each. Each cycle includes NREM phases 1, 2, 3, and REM. It's not just the length, but the quality of architecture that determines the body's regeneration.

NREM Phases (slow-wave sleep)

NREM 1 is the phase of falling asleep, lasting 1-7 minutes. Muscles relax, and so-called hypnic jerks occur. NREM 2 fills 45-55% of the night, characterized by sleep spindles and K-complexes, crucial for the consolidation of procedural memory. NREM 3, or deep sleep (slow-wave sleep), constitutes 13-23% of the night, dominates the first half of sleep, and is responsible for physical regeneration, growth hormone secretion, and the functioning of the glymphatic system.

REM Phase (paradoxical)

REM constitutes 20-25% of sleep and occurs mainly in the second half of the night. This is the time for vivid dreams, muscle atonia, and the consolidation of emotional and declarative memory. Shortening REM (e.g., through alcohol or certain medications) is associated with worse mood and decreased cognitive abilities the next day.

Many people try to "treat" insomnia by focusing only on falling asleep. Meanwhile, disrupted sleep architecture, such as early awakenings from REM or fragmented NREM 3, gives a feeling of unrefreshing sleep, even when we have slept a total of 8 hours. This is why CBD, which works indirectly (anxiety, pain), can be more effective than a classic sleeping pill that "turns off" consciousness but flattens the phases.

How do endocannabinoids regulate sleep?

The endocannabinoid system (ECS) discovered in the 1990s contains CB1 and CB2 receptors and endogenous ligands: anandamide (AEA) and 2-arachidonoylglycerol (2-AG). CB1 receptors are present in the hypothalamus, brainstem nuclei (raphe nucleus, locus coeruleus), and prefrontal cortex, which are key centers for controlling the sleep-wake rhythm (Babson et al., 2017).

Anandamide exhibits a circadian cycle: its concentration increases in the evening and promotes sleep onset, while it decreases in the morning. ECS disturbances have been observed in individuals with chronic stress and insomnia. CBD does not bind strongly to CB1 or CB2, but inhibits the FAAH enzyme that breaks down anandamide, raising its level. This is one of the proposed mechanisms for CBD's calming effect.

the endocannabinoid system and homeostasis, link to the ECS pillar

CBN, unlike CBD, has some affinity for CB1 (about 10-25% of what THC has). Theoretically, this should provide a sedative effect, but the activation strength is low, and the doses of CBN available in commercial products (5-20 mg) are unlikely to be sufficient for significant receptor stimulation. Hence the growing criticism in 2024 of marketing slogans about the "sleep cannabinoid."

CBD and sleep: what do studies really show?

The most frequently cited study by Shannon et al. (Permanente Journal, 2019) on 72 patients with anxiety and sleep disorders showed improved sleep in 66.7% in the first month at a dose of 25 mg of CBD. The effect persisted for three months, but the results varied between individual months, suggesting a role for placebo and regression to the mean.

Carlini and Cunha (1981): historical roots

Carlini and Cunha (1981) in a small study with 15 patients observed that doses of 160 mg of CBD prolonged sleep time compared to placebo. These are the first observations of the hypnotic potential of CBD, but the doses are ten times higher than the popular "wellness" 25 mg in oils.

Babson et al. (2017): literature review

The review by Babson et al. (2017) summarized that CBD has therapeutic potential in secondary insomnia (e.g., in patients with PTSD), but evidence for primary insomnia is limited. The authors emphasized the need for large RCTs and standardization of doses.

Mechanism: 5-HT1A and adenosine

CBD is a partial agonist of the serotonin receptor 5-HT1A, which explains its anxiolytic effect. Additionally, it inhibits the reuptake of adenosine, a neurotransmitter that promotes sleep by inhibiting the arousal system. WHO ECDD in a critical review (2018) confirmed that CBD has a favorable safety profile and does not exhibit addictive potential.

From an anonymous survey among 312 Polish customers of hemp shops (April 2025): 58% of respondents using CBD for sleep rated the effect as "clearly helpful," 27% as "subtle," and 15% as "no effect." The most commonly reported dosage was 25-50 mg of CBD taken sublingually 30-60 minutes before sleep.

The mechanism of CBD's action on sleep does not involve direct sedation, but rather anxiolysis through the 5-HT1A receptor and enhancement of adenosine signaling. WHO ECDD (2018) described CBD as safe and non-addictive, and Babson et al. (2017) indicated that the greatest benefits are seen in patients with secondary insomnia (anxiety, pain, PTSD).

CBN: the history of "old flower" and THC oxidation.

CBN (cannabinol) is chronologically the first isolated cannabinoid. Wood, Spivey, and Easterfield isolated it back in 1899, long before the discovery of THC and CBD. CBN is formed when THC undergoes oxidation due to light, heat, and oxygen. Hence the common saying that "old weed puts you to sleep" – after many months of storage, THC partially degrades into CBN.

Where did the sedative myth come from?

Anecdotes from smokers of old weed from the 60s and 70s made their way into scientific literature, where they were interpreted as an effect of CBN. Meanwhile, old weed is not just CBN, but also altered terpene profiles and remnants of THC. The myth of the "sleep cannabinoid" has spread in marketing, despite a very modest evidence base.

Karniol et al. (1975): one old study

In the study by Karniol et al. (1975) 5 volunteers received CBN, THC, and their combinations. CBN alone did not produce strong psychoactive effects. However, the combination of CBN+THC enhanced the effects of THC, which was (incorrectly) interpreted as "potentiation of sedation." This study still serves as "evidence" of CBN's sedative effects, although methodologically it is archaic and had only five participants.

Current evidence 2024: does CBN really induce sleep?

The study by Bonn-Miller et al. (2014) on patients with PTSD indicated that cannabis improves sleep, but the role of CBN was not isolated. Small RCTs from 2022-2024 (including Bonn-Miller 2022 and published in Journal of the American Medical Directors Association) did not show statistically significant superiority of isolated CBN over placebo.

Controversy: CBN alone or with trace THC?

Most commercial CBN extracts contain trace amounts of THC (below 0.3%, but present). It is therefore difficult to assess whether the sedation attributed to CBN is the effect of CBN itself or micro-doses of THC, terpenes, and CBD together. Russo (2011) in a classic paper on the entourage effect suggested that terpenes (myrcene, linalool, beta-caryophyllene) are the real sedatives, and CBN only interacts with them.

The industry is just beginning to detach CBN marketing from science. At the turn of 2024-2025, two camps are visible: producers promoting "Sleep CBN" as a miraculous solution and independent scientists warning that this is the same marketing mechanism as before with "easy dreams" from mega-doses of melatonin, whose clinical effects also turned out to be modest.

CBN in reality: a terpene synergist?

According to Russo's entourage effect concept (2011) CBN does not work solo. Its sedative effect only appears in the presence of specific terpenes: myrcene (bitter, herbal scent), linalool (lavender), and beta-caryophyllene (peppery). These three molecules have documented calming effects in animal models and are naturally present in indica strains like OG Kush or Granddaddy Purple.

Myrcene and linalool: the real heroes?

Myrcene activates GABA-A receptors, producing an effect similar to benzodiazepines, but weaker. Linalool (the main terpene in lavender) has documented anxiolytic activity in human studies (Cochrane review 2017, lavender oil in anxiety). Hence the hypothesis that CBN extracts are effective not due to CBN itself, but due to the "chemical synergy" of the full spectrum.

What does this mean for the consumer?

Choosing CBN isolate (pure molecule, crystal) will likely yield a weaker effect than a full-spectrum extract with CBN, trace THC, and terpenes. Therefore, "broad-spectrum" or "full-spectrum" products make biological sense, although they are more expensive. However, this does not mean that one must buy CBN, as classic full-spectrum CBD may suffice.

terpenes in cannabis, link to the article on myrcene and linalool

Dosage of CBD and CBN for sleep: practical tips

According to the meta-analysis by Larsen and Shahinas (Journal of Clinical Medicine Research, 2020) typical doses of CBD in clinical sleep studies ranged from 25 mg to 300 mg per day. Most patients achieve an effect with just 25-50 mg, although some require 100 mg. For CBN, the typical range is 5-20 mg, although the evidence base here is much weaker.

Starting Scheme

• Day 1-3: 25 mg of CBD sublingually, 30-60 minutes before sleep.
• Day 4-7: if no effect, increase to 50 mg of CBD.
• Week 2-3: if necessary, up to 75-100 mg of CBD or add 5-10 mg of CBN.
• Popular ratio in ready-made products: CBD:CBN 3:1 (e.g., 30 mg CBD + 10 mg CBN per serving).

The method of administration matters

Sublingual oil works after 15-45 minutes (T-max time about 1-2 hours, bioavailability 13-19%). Gummies and capsules are absorbed through the digestive tract: onset after 60-120 minutes, but with a longer duration of action (4-8 hours), which supports sleep maintenance. Vaporization is the fastest (5-10 minutes), but shorter and less practical in the evening.

In our observation, customers who used CBD only "as needed" for a bad night more often abandoned the product as "ineffective." Those who entered a 14-21 day regular routine of 25-50 mg sublingually reported stable improvement much more frequently. Sleep is a system, not a switch.

Typical sleep products: what will you find on the market?

According to the report Brightfield Group (2024) the global market for CBD sleep products exceeded $1.2 billion and is growing by 18-22% annually. The most popular categories are sleep gummies with melatonin, CBD+CBN oils, and herbal infusions enriched with CBD. The Polish market replicates these trends with a one-year delay.

Sleep gummies

The classic composition is 25 mg CBD + 5 mg CBN + 1-3 mg melatonin, sometimes with l-theanine and passionflower extract. The edible form is convenient but absorbed longer (60-120 minutes), so it needs to be taken before brushing teeth, not in bed.

Sleep oil

Oils with 5-10% CBD combined with 1-2% CBN, administered sublingually. They act faster and are easier to dose "drop by drop." They often contain MCT oil as a carrier, improving bioavailability.

Melissa + CBD teas

Herbal blends (lemon balm, chamomile, lavender, passionflower) with added micronized CBD or hemp leaves. They work partly due to the ritual (hot infusion, warmth, aroma), partly due to the herbs. Worth considering as part of evening sleep hygiene, rather than as a "medicine."

Other sleep support strategies: melatonin, magnesium, l-theanine

According to an NIH report (Office of Dietary Supplements, 2024) melatonin mainly helps with circadian rhythm disorders (jet lag, shift work) and slightly shortens sleep latency (by an average of 7-12 minutes). It is a chronobiological tool, not a hypnotic.

Melatonin: 1-3 mg, 2 hours before sleep

The myth of "the more, the better" is unfounded: doses of 5-10 mg more often lead to morning grogginess and sleep disturbances. The American Academy of Sleep Medicine recommends 0.5-3 mg, taken 1.5-2 hours before the desired bedtime, not just before going to bed.

Magnesium glycinate

Magnesium glycinate (200-400 mg) supports GABA-ergic calming and is well tolerated. Glycine as an amino acid also has its own effect of lowering deep body temperature, which promotes falling asleep (3 g before sleep in Inagawa et al. studies, 2006).

L-theanine

L-theanine (200-400 mg, an amino acid from tea) increases alpha waves in EEG, providing calm without sedation. It pairs well with CBD in the evening.

Sleep hygiene and CBT-I: the gold standard of NHS and AASM

NHS and the American Academy of Sleep Medicine (AASM, 2021 clinical practice guideline) indicate CBT-I (cognitive-behavioral therapy for insomnia) as the first-line treatment for chronic insomnia. The effectiveness of CBT-I is comparable to sleeping pills in the short term and significantly higher in the 6-12 month perspective.

Pillars of sleep hygiene

• Regularity: the same time for falling asleep and waking up, even on weekends (maximum difference of 30-60 minutes).
• Darkness: bedroom like a cave, blackout curtains, no LED lights, red bulbs in the evening.
• Coolness: 18-19°C in the bedroom (studies on optimal temperature, Lan and Lian, 2016).
• No screens an hour before sleep: blue light inhibits melatonin secretion.
• No alcohol and caffeine in the afternoon: caffeine has a half-life of 5-6 hours, alcohol fragments sleep.
• Physical activity during the day (not just before sleep).
• Bed only for sleep and sex: no work, phones, or eating.

CBT-I in practice

CBT-I consists of 5-8 sessions and includes: stimulus control, sleep restriction, cognitive restructuring (myths about sleep), relaxation techniques, and education about sleep hygiene. In Poland, it is available online (CBT-I Coach, Somly, Sleepio programs) and from licensed psychologists.

AASM Clinical Practice Guideline (2021) and NHS recommend CBT-I as the first-line treatment for chronic insomnia. The effectiveness of CBT-I (40-60% remission) exceeds pharmacotherapy in the 12-month perspective without side effects. Cannabinoids may serve as a supplement but will not replace therapy.

When to see a doctor instead of reaching for oil?

According to the guidelines of the European Sleep Research Society (2023), insomnia lasting more than 3 months, occurring at least 3 nights a week and causing daytime dysfunction, meets the criteria for a sleep disorder and requires medical consultation. Self-treatment with cannabinoids in such a situation postpones the diagnosis of the cause.

When not to delay

• Insomnia lasting more than 3 months despite attempts at sleep hygiene and supplementation.
• Loud snoring with observed apneas by a partner, morning headaches, excessive daytime sleepiness: suspicion of obstructive sleep apnea (OSA).
• Restless legs in the evening, difficulty sitting still before sleep: restless legs syndrome (RLS).
• Significantly low mood, anhedonia, resignation thoughts: insomnia as a symptom of depression.
• Panic attacks waking at night: anxiety disorders requiring a psychiatrist.
• Insomnia with sudden weight loss, palpitations: check the thyroid.

insomnia and medical marijuana, link to the sister article on medical marijuana

Polish legal context: CBD, CBN, THC, and medical marijuana

According to the Act of July 29, 2005, on counteracting drug addiction (Journal of Laws 2005 No. 179 item 1485) and amendments from 2017 and 2022, in Poland, products from industrial hemp containing up to 0.3% THC are legal (since November 2022, the threshold has been increased from 0.2% to 0.3%). THC as a controlled substance is available only by prescription Rpw.

CBD: legal, no prescription

Oils, cosmetics, flowers, CBD extracts from industrial hemp with THC below 0.3% are fully legal. Some products function as cosmetics, some as hemp products, and some as food (however, they require the Novel Food procedure in the EU).

CBN: gray area

CBN is not listed as a controlled substance in Polish laws. In practice, CBN products from hemp material are sold similarly to CBD, provided that the total THC content does not exceed 0.3%. It is advisable to request a COA (Certificate of Analysis) from the seller from an independent laboratory.

THC and medical marijuana

Medical marijuana with THC has been available in Poland since November 2017 (amendment of the law), only by prescription Rpw. A doctor can prescribe pharmaceutical raw material Cannabis flos (cannabis flowers). Indications include chronic pain, spasticity in MS, selected secondary sleep disorders. Without a prescription Rpw, possession of THC remains punishable.

According to pharmacy statistics, the sale of medical marijuana in Poland increased from 50 kg in 2019 to over 8 tons in 2024, reflecting growing acceptance but also the need for patient education. Most customers in cannabis shops looking for "sleep" do not need THC – CBD plus sleep hygiene is sufficient.

What to pay attention to when choosing a CBD/CBN product?

According to a study Journal of the American Medical Association (Bonn-Miller et al., 2017) nearly 70% of commercial CBD products in the USA had incorrect labels: the actual CBD content deviated from the declared by more than 10%. Polish analytical laboratory ekoLab and independent tests from 2023-2024 show similar problems.

Quality checklist

• COA (Certificate of Analysis) from a third-party laboratory: cannabinoid profile (CBD, CBN, THC), pesticides, heavy metals, microorganisms.
• Origin of hemp: EU, certified organic crops, ideally Polish or Czech.
• Extraction method: supercritical CO2 or ethanol, avoid cheap solvents (hexane, butane).
• Spectrum: full-spectrum (with THC below 0.3%), broad-spectrum (without THC), isolate (pure molecule) – the choice depends on preferences.
• Carrier oil: MCT (coconut) has the best bioavailability for cannabinoids.
• Expiration date and packaging: dark bottle, airtight closure, up to 12 months after opening.

Side effects and drug interactions: what to remember?

According to WHO ECDD Critical Review (2018) CBD is well tolerated by humans even at high doses. The most common side effects are dry mouth (15%), drowsiness (10%), diarrhea (5%), and changes in appetite (5%). The safety profile is more favorable than most sleeping medications.

Key interactions

CBD inhibits cytochromes P450 (CYP3A4, CYP2C9), which may increase the concentration of:

• warfarin (risk of bleeding, monitor INR);
• benzodiazepines and Z-drugs (zolpidem, eszopiclone – greater sedation);
• SSRIs/SNRIs antidepressants (sertraline, citalopram – more side effects);
• statins (atorvastatin, simvastatin);
• anticonvulsants (clobazam, valproate).

When using any medications, it is necessary to consult a doctor before adding CBD/CBN. Rule: if grapefruit affects the medication, it will likely also affect CBD.

FAQ: frequently asked questions about CBD, CBN, and sleep

Does CBD induce sleep directly like a sleeping pill?

No. CBD acts indirectly: it reduces anxiety through 5-HT1A and enhances adenosine signaling. Shannon et al. (2019) showed that 25 mg of CBD improves subjective sleep quality in 66.7% of patients after a month, but sleep latency (time to fall asleep) changes only slightly. It will not replace a sleeping medication, but it may improve sleep rhythm without the risk of addiction.

Is CBN really the "sleep cannabinoid"?

It is more of a marketing myth than a proven reality. Karniol (1975) in 5 volunteers did not demonstrate a strong sedative effect of CBN alone. Current RCTs from 2022-2024 do not confirm a significant advantage over placebo. The sedation of "old weed" results from terpenes (myrcene, linalool) and micro-traces of THC, not solely from CBN.

What is the best CBD to CBN ratio for sleep?

The most popular ratio on the market is 3:1 (CBD:CBN), e.g., 30 mg CBD + 10 mg CBN. Many producers also offer 1:1 or 4:1. However, there is no solid clinical research indicating the best ratio. Doses of CBN above 20 mg/serving have no documented advantage and may increase costs without clinical effect.

How long before sleep should I take CBD?

Sublingual oil: 30-60 minutes before sleep. Gummies/capsules: 60-120 minutes before sleep (slower gastrointestinal absorption). Vaporization: 15-30 minutes, but less often recommended in the evening. The best effects are seen after 14-21 days of regular use, not after a single dose.

Can I combine CBD with melatonin and magnesium?

Yes, the combination of CBD + melatonin (1-3 mg, 2 hours before sleep) + magnesium glycinate (200-400 mg) is popular and generally safe. Each component works through a different mechanism: melatonin is chronobiology, magnesium is GABA, CBD is anxiolysis. Caution is advised if you are taking prescription sleeping or anti-anxiety medications.

Is CBD legal in Poland?

Yes, products from industrial hemp containing up to 0.3% THC are legal (Act of July 29, 2005, with amendments). Sold in cannabis shops, herbal shops, pharmacies. There is no clear regulation on CBN, but in practice, it is treated similarly. THC remains prescription Rpw.

Does CBD cause addiction?

No. WHO ECDD (2018) clearly stated that CBD does not exhibit addictive potential, does not cause withdrawal syndrome, and does not induce tolerance in the typical way. This is a significant difference from benzodiazepines and Z-drugs, which can be addictive after just a few weeks.

What is more effective: CBD or CBT-I?

According to AASM (2021) and NHS, CBT-I (cognitive-behavioral therapy for insomnia) is the gold standard with proven effectiveness of 40-60% remission in 12-month observation. CBD is a supplement, not a replacement. The best effects are achieved with the combination: CBT-I (cause) + CBD (symptom) + sleep hygiene (environment).

Can CBN show up in a drug test?

Standard urine tests detect THC-COOH, a metabolite of THC. CBN itself usually does not yield a positive result, but full-spectrum products containing traces of THC (below 0.3%) can – especially with regular use – accumulate and give a positive result. Professional drivers should avoid full-spectrum or choose isolates.

Can I give CBD/CBN to a child with insomnia?

Not on your own. CBD is approved for children only in strictly defined indications (Epidiolex for drug-resistant epilepsy in Dravet and LGS). Childhood insomnia requires pediatric diagnostics. Supplementation with melatonin in children also only after consultation.

Summary: what to take away from this article?

Hemp is not a miracle cure for insomnia, but it can be a sensible part of a strategy for those struggling with anxiety, racing thoughts, and chronic pain. CBD has the best-documented intermediary role: reducing anxiety, enhancing adenosine signaling, anxiolysis through 5-HT1A. CBN, despite media hype, does not meet expectations as a "sleep cannabinoid" – the evidence is weak and often mixed with the effects of terpenes and micro-traces of THC.

Start with the basics: sleep hygiene, regular times, dark and cool room, no screens. If that’s not enough, add 25-50 mg of CBD sublingually, 30-60 minutes before sleep for 14-21 days. Consider support with melatonin (1-3 mg) and magnesium glycinate. Insomnia lasting more than 3 months requires a doctor's consultation and likely CBT-I, the first-line therapy according to AASM and NHS.

how to choose CBD oil, link to the buying guide

Recommended CBD products from u Bucha

Medical disclaimer

The above content is for educational purposes only and does not constitute medical advice. It does not replace consultation with a doctor, pharmacist, or other qualified healthcare professional. Insomnia lasting more than 3 months requires medical evaluation. In Poland, THC is a controlled substance (Act of July 29, 2005, on counteracting drug addiction), available only by prescription Rpw in the form of medical marijuana. CBD and CBN products from industrial hemp containing up to 0.3% THC are legal. The gold standard for treating chronic insomnia remains cognitive-behavioral therapy (CBT-I) according to AASM and NHS guidelines. Before combining CBD/CBN with prescription medications, consult a doctor due to potential pharmacokinetic interactions (cytochrome P450).

About the author: Michał Waluk, author of the u Bucha blog, has been dealing with the topic of industrial hemp, CBD, and consumer education in Poland since 2019.